The pharmaceutical manufacturing sector confronts a transformative era in 2025 as revised U.S. tariffs on pharmaceuticals continuously redefine logistics frameworks, pricing architectures, and sourcing methodologies. These broad-spectrum pharmaceutical tariffs impact multiple domains—encompassing medical supplies, finished drug preparations, and active pharmaceutical ingredients...